Crohn's Colitis Professional

Current Status of Therapeutic Drug Monitoring in IBD

Current Status of Therapeutic Drug Monitoring in IBD
RestartResume

This is a module is one of two keynote presentations originally presented during the Crohn’s & Colitis Foundation Central Regional Professional Education Conference at Washington University: Cutting Edge Approaches to IBD Management on Sept 24, 2022.

Available credits: 0.50

Time to complete: 30 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    These presentations were recorded during the Crohn’s & Colitis Foundation Central Regional Professional Education Conference at Washington University in St. Louis: Cutting Edge Approaches in IBD Management in 2022 held September 24, 2022, and supported in part by unrestricted educational grants from Boehringer Ingelheim, Bristol Myers Squibb, Ferring Pharmaceuticals, Janssen, and Pfizer, Inc.

  • Learning Objectives

    The intended result of this activity is increased knowledge/competence, and upon completion of this course, participants should be able to:

    • Discuss studies to identify next generation IBD therapies
    • Analyze the literature of updates in use of anti-tnf and anti-integrin therapies in IBD
    • Describe the mechanism and rationale behind the development of targeted IL 12/23 and IL 23 inhibitors
    • Evaluate current efficacy and safety data for approved IL 23 inhibitors for the management of IBD and Crohn's disease
    • Identify the currently available janus kinase (JAK) inhibitors and S1P modulator for the treatment of moderate to severe ulcerative colitis
    • Implement the safety monitoring required prior to and during treatment with JAK inhibitors and S1P modulators
  • Target Audience

    This activity is designed for physicians and nurses to give updates and updated approaches to treatment of patients with inflammatory bowel diseases. This activity may also be of interest to nutritionists or anyone who specializes in gastroenterology, internal medicine, or surgery.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by the Crohn’s & Colitis Foundation and Washington University School of Medicine in St. Louis. Washington University School of Medicine in St Louis is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Credits Available for this Activity:

    American Medical Association (AMA Credit)
    Washington University School of Medicine in St. Louis designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    American Nurses Credentialing Center (ANCC Credit)
    Washington University School of Medicine in St. Louis designates this enduring material for a maximum of 0.5 ANCC contact hour. 

    Interprofessional Continuing Education (IPCE)
    This activity was planned by and for the healthcare team, and learners will receive a maximum of 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

  • Disclosure of Conflicts of Interest

    Planning Committee and disclosures

    All relevant financial relationships have been mitigated.

    Matthew Ciorba, MD
    Research Support/Grants – Janssen Pharmaceuticals
    Consulting / Executive Role / Advisory Committee – Bristol-Myers Squibb Co/BMS, Janssen Scientific Affairs LLC, Takeda Pharmaceuticals Company Ltd
    Authorship (e.g. book royalties or publication agreements) – Pfizer, Inc.

    Parakkal Deepak, MBBS, MS
    Research Support/Grants – Alimentiv Inc, Arena Pharmaceuticals Inc, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Co/BMS, Celgene Corporation, CorEvitas LLC, PredictImmune
    Consulting / Executive Role / Advisory Committee – AbbVie Inc, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Co/BMS, SCIPHER, South Asian IBD Alliance

    Sara Horst, MD, MPH
    Consulting / Executive Role / Advisory Committee – AbbVie Inc, Gilead Sciences, Janssen, Takeda Pharmaceuticals

    Dan Schneiderjohn, MPH
    No financial relationships to disclose

    Joanna Davidson Gilbertsen, RN, BSN
    No financial relationships to disclose

    Independent Reviewer:
    Kemmian D. Johnson, MD, MPH
    No financial relationships to disclose

    Disclosure Information: It is the policy of Washington University School of Medicine in St. Louis, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational activities. All planners, faculty and other persons who may influence content of this CME activity have disclosed all relevant financial relationships with commercial interests. All disclosures have been reported and are indicated with their presentations. Any potential conflicts were addressed and mitigated.

    All members of the CME department have nothing to disclose.

    Speakers are also expected to openly disclose inclusion of discussion of any off-label, experimental, or investigational use of drugs or devices in their presentations.

    Presentations are expected to be based on evidence that is accepted within the profession of medicine as adequate justification for their indication in the care of patients. All scientific research should conform to the generally accepted standards of experimental design, data collection and analysis.

    These presentations are not an endorsement of any commercial interests.

    These presentations are the views and experiences of the presenters. The presenters' views do not represent the policy or position of Washington University School of Medicine in St. Louis. Washington University School of Medicine in St. Louis, Continuing Medical Education, is the sponsor for CME credits.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments

Register

We’re glad to see you’re enjoying Crohn's Colitis Professional…
but how about a more personalized experience?

Register for free